The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study

References

• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice [Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice]. Eur Heart J 2003;24:1601–10
   Google Scholar
• Adult Treatment Panel III. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. J Am Med Assoc 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Fourth joint task Force of the European Society of Cardiology, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2007;14E1–E40
   Google Scholar
• Anon. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554–72
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Cater R, Pringle M, Coupland C. Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. Br Med J 2003;29: 326,689
   Google Scholar
• Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459–67
   PubMed Web of Science ®Google Scholar
• Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363–72
   PubMed Web of Science ®Google Scholar
• Knopp RH. Drug treatment of lipid disorders. New Engl J Med 1999;341:498–511
   PubMed Web of Science ®Google Scholar
• Gylling H. Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. Int J Clin Pract 2004;58:859–66
   PubMed Web of Science ®Google Scholar
• Stein E. Results of phase I/II clinica; trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J Supplements 2001;3:E11–E16
   Google Scholar
• Redgrave TG, Roberts DC, West CE. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem 1975;65:42–9
   Google Scholar
• Griffin BA, Caslake MJ, Yip B, et al. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 1990;83:59–67
   PubMed Web of Science ®Google Scholar
• Goldberg A, Sapre A, Liu J, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004;79:620–9
   PubMed Web of Science ®Google Scholar
• Ballantyne C, Blazing M, King T, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487–94
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464–73
   PubMed Web of Science ®Google Scholar
• Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006;22:2041–53
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007;23:1169–76
   PubMed Web of Science ®Google Scholar
• Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95:462–8
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AE, Bertone G, et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther 2004;26:1599–607
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. J Am Med Assoc 2004;15:1307–16
   Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. J Am Med Assoc 2005;16;2437–45
   Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Metaanalysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009–26
   PubMed Web of Science ®Google Scholar
• Bays H, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209–30
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78
   PubMed Web of Science ®Google Scholar
• Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001;104:387–92
   PubMed Web of Science ®Google Scholar
• Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels [The Regression Growth Evaluation Statin Study (REGRESS)]. Circulation 1995;91:2528–40
   PubMed Web of Science ®Google Scholar
• Kallio V, Hamalainen H, Hakkila J, et al. Reduction in sudden deaths by a multifactorial intervention programme after acute myocardial infarction. Lancet 1979;2:1091–4
   PubMed Web of Science ®Google Scholar
• Arntzenius AC, Kromhout D, Barth JD, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis [The Leiden Intervention Trial]. New Engl J Med 1985;312:805–11
   PubMed Web of Science ®Google Scholar
• Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia [Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)]. New Engl J Med 1990;323:946–55
   PubMed Web of Science ®Google Scholar
• Anon. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984;251:351–64
   Web of Science ®Google Scholar
• Sacks FM, Pasternak RC, Gibson CM, et al. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients [Harvard Atherosclerosis Reversibility Project (HARP) Group]. Lancet 1994;344:1182–6
   PubMed Web of Science ®Google Scholar
• Rossebo AB, Pedersen TR, Allen C, et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 2007;99:970–3
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Sager PT, de Groot E, et al. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 2005;149:234–9
   Google Scholar
• Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003;84:S207–S210
   PubMed Web of Science ®Google Scholar